CDER Brand Name Reviews: Predictability Returns To Process
This article was originally published in RPM Report
FDA’s Center for Drug Evaluation & Research is now granting 86% of drug sponsors’ preferred proprietary trade names prior to launch – a significant improvement over just five years ago. Better communication between FDA and drugs sponsors – including the development of several new guidance documents – has resulted in a much more predictable review of proprietary trade names.
You may also be interested in...
FDA Rejecting Fewer Proprietary Names
The Center for Drug Evaluation & Research granted 74% of the proprietary names it evaluated between October 1, 2013 and August 31, 2014. That is a big improvement from rejection rates of over 50% just a few years ago.
What’s In A Name? Janssen’s Loss Of Sovriad Was Gilead’s Gain With Sovaldi
FDA initially rejected both sponsors’ preferred proprietary names for their hepatitis C treatments due to the risk of confusion with each other. Janssen had to settle for Olysio, its backup name for simeprevir, leaving Gilead to claim title to its preferred name for sofosbuvir.
AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions
The medullary thyroid cancer drug's Risk Evaluation and Mitigation Strategy requires mandatory enrollment and certification of prescribers and pharmacists, which should help ensure the drug is used primarily in patients with symptomatic, progressive disease.